Analysis clinical features of COVID-19 infection in secondary epidemic area and report potential biomarkers in evaluation

Weiping Ji; Gautam Bishnu; Zhenzhai Cai; Xian Shen

is the (which was not peer-reviewed) The copyright holder for this preprint . https://doi.org/10.1101/2020.03. 10.20033613 doi: medRxiv preprint ± 0.30 × 10 9 /L, the monocyte count was 0.32 (0.24-0.48) × 10 9 /L, the eosinophil count was 0.01 (0.00-0.02) × 10 9 /L, the eosinophil basic granulocyte count was 0.01 (0.01-0.02) × 10 9 /L, hemoglobin (Hb) was 143.33 ± 15.96 g/L, the red blood cell count was 4.93 ± 0.44 × 10 9 /L, the platelet (PLT) count was 187.62 ± 39.55 × 10 9 /L, and C-reactive protein (CRP) was 11.89 (9.74-23.36) mg/ L; neutrophil ratios and other data are shown in Table 2. 2.3 Serum amyloid protein A (SAA) test: Among the 33 patients enrolled in the study, 5 patients in the DC group were tested for serum amyloid protein A (SAA). It was found that SAA in 4 patients was increased significantly, with an average value of 61.51 mg/L (normal value ≤ 10) mg/L). The increase in this protein was more obvious than the increase in CRP, but due to the limited data, a comparative statistical analysis was not performed. In the future, we will focus on the SAA of NCP patients. See Table 3 for the detailed data.